Systemic Sclerosis-related ILD

Chapters

 

REFERENCES

  1. Solomon JJ, Olson AL, Fischer A, et al. Scleroderma lung disease. Eur Respir Rev. 2013;22(127):6-19. doi: 10.1183/09059180.00005512.
  2. Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685-1699. doi: 10.1016/S0140-6736(17)30933-9.
  3. Nevares A. Systemic Sclerosis. Merck Manual website.https://www.merckmanuals.com/professional/musculoskeletal-and-connective-tissue-disorders/autoimmune-rheumatic-disorders/systemic-sclerosis. February 2018. Accessed September 18, 2018.
  4. Furst DE, Fernandes AW, Iorga SR, et al. Epidemiology of systemic sclerosis in a large US managed care population. J Rheumatol. 2012;39(4):784-6. doi: 10.3899/jrheum.111106.
  5. Robinson D, Eisenberg D, Nietert PJ, et al. Systemic sclerosis prevalence and comorbidities in the US, 2001-2002. Curr Med Res Opin. 2008;24(4):1157-66. doi: 10.1185/030079908x280617.
  6. Mayes MD, Lacey JV, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003;48(8):2246-2255. doi: 10.1002/art.11073.
  7. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360(19):1989-2003. doi: 10.1056/NEJMra0806188.
  8. Ha Y-J, Lee YJ, Kang EH. Lung Involvements in Rheumatic Diseases: Update on the Epidemiology, Pathogenesis, Clinical Features, and Treatment. Biomed Res Int. 2018; doi: 10.1155/2018/6930297.
  9. Shenavandeh S, Naseri R. Assessment of hospitalization and mortality of scleroderma in-patients: a thirteen-year study. Reumatologia. 2017;55(4)163-168. doi: 10.5114/reum.2017.69776.
  10. Denton CP, Lapadula G, Mouthon L, et al. Renal complications and scleroderma renal crisis. Rheumatology (Oxford). 2009;48 suppl 3:iii32-5. doi: 10.1093/rheumatology/ken483.
  11. Solomon JJ et al. Int. J. Clin. Rheumatol. 2011;6(5):503-515.
  12. Schoenfeld SR, Castelino FV. Evaluation and management approaches for scleroderma lung disease. Ther Adv Respir Dis. 2017;11(8):327-340. doi: 10.1177/1753465817713680.
  13. Castelino FV, Varga J. Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management. Arthritis Res Ther. 2010;12(4):213. doi: 10.1186/ar3097.
  14. Ranu H, Wilde M, Madden B. Pulmonary function tests. Ulster Med J. 2011;80(2):84-90.
  15. Gigante A, Fanelli FR, Lucci S, et al. Lung ultrasound in systemic sclerosis: correlation with high-resolution computed tomography, pulmonary function tests and clinical variables of disease. Intern Emerg Med. 2016;11(2):213-217. doi: 10.1007/s11739-015-1329-y.
  16. Robles-Perez A, Molina-Molina M. Treatment Considerations of Lung Involvement in Rheumatologic Disease. Respiration. 2015;90(4):265-274. doi: 10.1159/000441238.
  17. Spagnolo P, Cordier J-F, Cottin V. Connective tissue diseases, multimorbidity and the ageing lung. Eur Respir J. 2016;47(5):1535-1558. doi: 10.1183/13993003.00829-2015.
  18. Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327-1339. doi: 10.1136/annrheumdis-2016-209909.
  19. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006; 354(25):2655-2666. doi: 10.1056/NEJMoa055120.
  20. Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016 Sep; 4(9):708-719. doi: 10.1016/S2213-2600(16)30152-7.
  21. Koo S-M, U S-T. Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist's point of view. Korean J Intern Med. 2017;32(4):600-610. doi: 10.3904/kjim.2016.212.
  22. Cappelli S, Randone SB, Camiciottoli G, et al. Interstitial lung disease in systemic sclerosis: where do we stand? Eur Respir Rev. 2015;24(137):411-9. doi: 10.1183/16000617.00002915.
  23. Yatsuoka H. Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis. Clin Med insights Circ Respir Pulm Med. 2016;9(suppl 1):97-110. doi: 10.4137/CCRPM.S23315.
  24. Silver KC, Silver RM. Management of Systemic-Sclerosis-Associated Interstitial Lung Disease. Rheum Dis Clin North Am. 2015;41(3):439-457. doi: 10.1016/j.rdc.2015.04.006.

See also

Test your Knowledge
Test your knowledge

Take the test

Lung X-Ray Example
Rad Rounds Mobile App

Download the app

Interstitial lung disease in systemic sclerosis with a focus on chest CT

Media Library

See Media